XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer

The purpose of this study is to determine how well the study drug XL092 is helping to treat a participant's cancer after 16 weeks of treatment. Researchers will also look at how safe the XL092 is and how well the XL092 is working. XL092 is an oral tablet that will be taken once a day. Participants will return to clinic for regular visits for checkups and tests.

Trial Details

NCT ID
NCT06568562
Phase
PHASE2
Sponsor
University of Utah
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • XL092
Locations (sample)
  • Salt Lake City, Utah, United States|40.76078,-111.89105

Key Eligibility Criteria

  • Participant aged ≥ 18 years
  • Disease criteria:
  • -Histologically or cytologically confirmed prostatic adenocarcinoma without small cell histology
  • Radiographic evidence of metatstatic disease

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →